Home / News

2025-10-14: EP4 Antagonist KF-0210 Phase II Clinical Trial for Osteoarthr...

The Phase II clinical trial of KF0210, an EP4 antagonist independently developed by Keythera Pharmaceuticals, for the treatment of knee osteoarthriti...

2020-09-28

Keythera completed RMB 100M Series A financing

Recently, Keythera (Suzhou) Biopharmaceutical Co., Ltd., an innovative drug research and development enterprise, announced the completion of a Series A financing of nearly RMB 100 million....

More >>

Home
Before
1
2
Next
Back